| Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority … AM Brunt, JS Haviland, DA Wheatley, MA Sydenham, A Alhasso, ... The Lancet 395 (10237), 1613-1626, 2020 | 825 | 2020 |
| 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial A Goldhirsch, RD Gelber, MJ Piccart-Gebhart, E De Azambuja, M Procter, ... The Lancet 382 (9897), 1021-1028, 2013 | 666 | 2013 |
| Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised … CE Coles, CL Griffin, AM Kirby, J Titley, RK Agrawal, A Alhasso, ... The Lancet 390 (10099), 1048-1060, 2017 | 592 | 2017 |
| Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor … SRD Johnston, LS Kilburn, P Ellis, D Dodwell, D Cameron, L Hayward, ... The Lancet Oncology 14 (10), 989-998, 2013 | 332 | 2013 |
| Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial P Schmid, J Abraham, S Chan, D Wheatley, AM Brunt, G Nemsadze, ... Journal of Clinical Oncology 38 (5), 423-433, 2020 | 331 | 2020 |
| First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015) FAST Trialists Group Radiotherapy and Oncology 100 (1), 93-100, 2011 | 285 | 2011 |
| International guidelines on radiation therapy for breast cancer during the COVID-19 pandemic CE Coles, C Aristei, J Bliss, L Boersma, AM Brunt, S Chatterjee, G Hanna, ... Clinical Oncology 32 (5), 279-281, 2020 | 267 | 2020 |
| Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer AM Brunt, JS Haviland, M Sydenham, RK Agrawal, H Algurafi, A Alhasso, ... Journal of Clinical Oncology 38 (28), 3261-3272, 2020 | 239 | 2020 |
| Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer CJ Poole, HM Earl, L Hiller, JA Dunn, S Bathers, RJ Grieve, DA Spooner, ... New England Journal of Medicine 355 (18), 1851-1862, 2006 | 239 | 2006 |
| Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial AM Brunt, D Wheatley, J Yarnold, N Somaiah, S Kelly, A Harnett, C Coles, ... Radiotherapy and Oncology 120 (1), 114-118, 2016 | 220 | 2016 |
| European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for … I Meattini, C Becherini, L Boersma, O Kaidar-Person, GN Marta, ... The Lancet Oncology 23 (1), e21-e31, 2022 | 178 | 2022 |
| Efficacy and safety analysis of nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase III clinical trial EA Mittendorf, B Lu, M Melisko, J Price Hiller, I Bondarenko, AM Brunt, ... Clinical Cancer Research 25 (14), 4248-4254, 2019 | 163 | 2019 |
| Fulvestrant plus vistusertib vs fulvestrant plus everolimus vs fulvestrant alone for women with hormone receptor–positive metastatic breast cancer: the MANTA phase 2 randomized … P Schmid, M Zaiss, C Harper-Wynne, M Ferreira, S Dubey, S Chan, ... JAMA oncology 5 (11), 1556-1564, 2019 | 92 | 2019 |
| 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial P Hoskin, B Popova, O Schofield, C Brammer, M Robinson, AM Brunt, ... The Lancet Oncology 22 (3), 332-340, 2021 | 79 | 2021 |
| AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled … P Schmid, J Abraham, S Chan, D Wheatley, M Brunt, G Nemsadze, ... J Clin Oncol 36 (15_suppl), 1007, 2018 | 79 | 2018 |
| Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial G Velikova, LJ Williams, S Willis, JM Dixon, J Loncaster, M Hatton, ... The Lancet Oncology 19 (11), 1516-1529, 2018 | 69 | 2018 |
| Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK … D Cameron, JP Morden, P Canney, G Velikova, R Coleman, J Bartlett, ... The Lancet Oncology 18 (7), 929-945, 2017 | 69 | 2017 |
| Outcomes from elective colorectal cancer surgery during the SARS‐CoV‐2 pandemic COVIDSurg Collaborative, JC Glasbey, D Nepogodiev, JFF Simoes, ... Colorectal Disease 23 (3), 732-749, 2021 | 68 | 2021 |
| FAST phase III RCT of radiotherapy hypofractionation for treatment of early breast cancer: 10-year results (CRUKE/04/015) AM Brunt, J Haviland, M Sydenham, H Algurafi, A Alhasso, P Bliss, ... International Journal of Radiation Oncology* Biology* Physics 102 (5), 2018 | 61 | 2018 |
| Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised … MT King, EK Link, TJ Whelan, IA Olivotto, I Kunkler, AH Westenberg, ... The Lancet Oncology 21 (5), 685-698, 2020 | 55 | 2020 |
